Author: Jupiter Life Science Consulting

COVID-19’s Impact on Oncology In response to COVID-19, global healthcare systems and life sciences research have been harnessed by the need to fight the public health crisis, ushering in enormous challenges in critical therapeutic areas as resources are diverted to address the pandemic. Cancer, with 18...

November 2020 In October 2020, UnitedHealthcare introduced an Accumulator Adjustment Medical Benefit Program, the first of its kind to be specific to the medical benefit [1]. Accumulator programs aim to leverage the copay assistance programs offered by the manufacturer, to prevent them from counting towards a...

Critical Challenges and Opportunities Even in non-pandemic times, rare and ultra-rare disease communities face staggering challenges as they work ceaselessly for awareness, support and treatment. It’s crucial to examine the impact of COVID-19 on rare diseases, which can help shed light on heightened hurdles as well...

Is it Time for Digital Health to Break Out of Isolation? The United States has been in an ongoing battle with substance addiction and opioid overdose, which has resulted in high rates of mortality; now with COVID-19, we are facing increased social isolation, more mental health...

In June 2020, the Health Resources and Services Administration (HRSA) reported that net purchasing volume under the 340B program in 2019 was at least $29.9 billion. This accounts for purchases made through wholesalers and excludes direct-from-manufacturer and some specialty distributor purchases – the total volume...

With the recent publication of American Patients First, the Trump administration has provided what it describes as a “blueprint to lower drug prices and reduce patient out-of-pocket costs.” Less a blueprint than a general position document, American Patients First is light on details and heavy...

BOSTON – Dec. 12, 2017 – Jupiter Life Science Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, today announced the acquisition of Alta Bioscience Consulting. Alta is a global provider of advisory services in the development and commercialization of...